x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers

On a mission to disseminate information to the community and bridge the gap between academia and community oncology in this rapidly changing field of hematology & oncology. Drs. Rahul & Rohit Gosain interview world-renowned hematologists/oncologists to present the practice-changing data in a small bite-sized format where one could immediately apply that information in their daily practice to provide the best cancer care to their patients close to home.

health & fitness medicine

All Episodes

00:21:02

Challenging Cases of Iron Abnormalities, Anemia or...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/04

Welcome to the Oncology Brothers podcast! In this episode, we dived into the complexities of non-malignant hematology, focusing on iron abnormalities—both deficiency and overload. We welcomed Dr. Marina Beltrami from The Ohio State University, who guided us through three challenging clinical scenarios:1. Anemia in Pregnancy: We discussed a 34-year-old woman in her second trimester with low MCV and ferritin levels, exploring treatment options including the safety and efficacy of IV iron versus oral

en

00:21:31

FDA Approval of Epcoritamab-Rituximab-Lenalidomide...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/04

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting

en

00:21:31

FDA Approval of Epcoritamab-Rituximab-Lenalidomide...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/12/01

In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.Key topics included:• The mechanism of action of Epcoritamab as a bispecific antibody targeting

en

00:22:36

Challenging Cases in Second Line & Beyond Renal Cell...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/30

In this episode of the Oncology Brothers podcast, we dive into the rapidly evolving landscape of renal cell carcinoma (RCC) treatment, focusing on second-line therapies. We were joined by Dr. David Braun, a GU Medical Oncologist from Yale University, to discuss two challenging real-life cases.We explored the current standard of care for metastatic RCC, including the use of immune-oncology (IO) therapies and tyrosine kinase inhibitors (TKIs). Dr. Braun shared insights on treatment options following

en

00:17:29

FDA Approval of Durvalumab with FLOT in Resectable...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/26

In this episode of The Oncology Brothers, we dived into the pivotal study of MATTERHORN, which explored the addition of Durvalumab to perioperative FLOT chemotherapy for patients with resectable gastric and gastroesophageal junction adenocarcinoma.Join us as we welcome Dr. Yelena Y. Janjigian, a medical oncologist from Memorial Sloan Kettering and the lead author of the MATTERHORN study. Dr. Janjigian shared insights on the study's design, findings, and the implications for clinical practice,

en

00:23:30

Challenging Cases in Breast Cancer with CDK 4/6...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/24

In this episode of the Oncology Brothers podcast, we took a deeper dive into the evolving landscape of CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Joined by esteemed oncologists Dr. Sara Tolaney from Dana-Farber Cancer Institute and Dr. Adam Brufsky from UPMC Hillman Cancer Center, the discussion focused on real-world scenarios involving adjuvant and metastatic settings.Key topics included:• The recent updates from the MonarchE and NATALEE trials, highlighting the

en

00:22:42

Challenging Cases in Non-Muscle Invasive Bladder...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/20

In this episode of the Oncology Brothers podcast, we dived deep into the rapidly evolving landscape of non-muscle invasive bladder cancer (NMIBC) treatment. Joined by expert guests Dr. Joshua Meeks, a urologist from Northwestern University, and Dr. Shilpa Gupta, a medical oncologist from Cleveland Clinic, the discussion focused on the integration of immunotherapy into non-muscle invasive bladder cancer.Key topics included:The definition and characteristics of high-risk non-muscle invasive bladder

en

00:20:23

FDA Approval of Ziftomenib (KOMET-001) in NPM1 mut...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/17

In this episode of the Oncology Brothers podcast, we dived into the exciting world of cancer treatment with a focus on the recent FDA approval of Ziftomenib for relapsed refractory NPM1 mutated acute myeloid leukemia (AML). We were joined by Dr. Eunice Wang from Roswell Park Comprehensive Cancer Center as our guest. Dr. Wang shared insights from the KOMET-001 study, detailing the study design, efficacy, and safety profile of Ziftomenib. With a response rate of nearly 30% and significant overall

en

00:16:11

Managing Toxicities of ROS1 Inhibitors in Non-Small...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/13

Welcome to the Oncology Brothers podcast! In this episode, we dive into the management of ROS1 fusion positive non-small cell lung cancer (NSCLC) and explore the various tyrosine kinase inhibitors (TKIs) available for this rare subset of patients.Join us along with special guest Dr. Estelamari Rodriguez, a thoracic medical oncologist from Sylvester Comprehensive Cancer Center, as we discussed:• The importance of comprehensive next-generation sequencing (NGS) in management of NSCLC.• A detailed

en

00:21:56

Managing Toxicities of Tyrosine Kinase Inhibitors...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/10

In this episode of the Oncology Brothers podcast, we are joined by esteemed hematologists Dr. Onyee Chan from Moffitt Cancer Center and Dr. Fadi Haddad from MD Anderson to discuss the management of side effects associated with tyrosine kinase inhibitors (TKIs) used in the treatment of chronic myeloid leukemia (CML).Join us as we delve into:• An overview of the different generations of TKIs, including imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib.• Common class-wide toxicities

en

00:24:35

Lung Cancer ESMO 2025 Highlights: MDT-BRIDGE,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/06

Welcome to another episode of the Oncology Brothers podcast! In this episode, we are joined by Dr. Rami Manochakian from the Mayo Clinic to discuss the latest practice-changing studies presented at ESMO 2025, focusing on lung cancer.Episode Highlights:• MDT-BRIDGE: Trial for resectable and borderline resectable non-small cell lung cancer (NSCLC) stressing the importance of a multidisciplinary approach.• FLAURA2 Update: showcasing the overall survival benefits of osimertinib combined with

en

00:19:20

GI Cancer ESMO 2025 Highlights: DYNAMIC-III, PEGASUS,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/11/03

In this episode of the Oncology Brothers podcast, we dived into the key takeaways from ESMO 2025, focusing on gastrointestinal (GI) malignancies. Join us as we welcomed Dr. Rachna Shroff, a GI medical oncologist from the University of Arizona, to discuss the latest studies and their implications for clinical practice.Episode Highlighted:•⁠ ⁠ctDNA in Colorectal Cancer: DYNAMIC-III and PEGASUS studies, examining the evolving role of ctDNA as a prognostic and potential predictive tool in early-stage

en

00:22:16

Breast Cancer ESMO 2025 Highlights: MonarchE,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/30

In this episode of the Oncology Brothers podcast, we are joined by Dr. Virginia Kaklamani from UT San Antonio to discuss the practice changing/informing findings from ESMO 2025, particularly in the realm of breast cancer.We dived deep into the most impactful studies, including:• MonarchE/NATALEE: Discover additional follow-up results from abemaciclib and ribociclib, where abemaciclib now has overall survival benefit in adjuvant HR+ settings.• Metastatic HR+ Disease: Insights on the latest data

en

00:15:12

Current Treatment Landscape of Ovarian Cancer with...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/27

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Sharyn Lewin, the Director of Gynecology Oncology at Holy Name Medical Center, to explore the evolving treatment landscape of ovarian cancer.Join us as we discuss:• The importance of surgical staging and debulking surgery in ovarian cancer treatment.• The role of neoadjuvant chemotherapy and the significance of germline testing.• Current systemic treatment paradigms, including the use of PARP inhibitors and

en

00:22:47

GU Cancer ESMO 2025 Highlights: PSMAddition,...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/23

In this episode of the Oncology Brothers podcast, we dive into the groundbreaking data presented at ESMO 2025, focusing on the GU landscape, particularly prostate and bladder cancer. Join us as we welcome Dr. Stephanie Berg, a GU medical oncologist from the Dana-Farber Cancer Institute, to discuss key studies and their implications for patient care.Episode Highlights:•⁠ ⁠PSMAddition: Explore the benefits of lutetium PSMA in metastatic hormone-sensitive prostate cancer, including improved

en

00:17:39

Challenging Cases with Metastatic EGFR Mutated...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/20

Join us for another insightful episode of The Oncology Brothers as we dive into the Challenging Case Series! In this episode, we were joined by Dr. Eric Singhi, a thoracic medical oncologist from MD Anderson, to discuss the complexities of treating EGFR-positive non-small cell lung cancer (NSCLC).We explored the latest treatment options, including:•⁠ ⁠Osimertinib•⁠ ⁠Amivantamab plus Lazertinib (based on the MARIPOSA trial)•⁠ ⁠Osimertinib plus chemotherapy (from the FLAURA2 trial)Listen in as we

en

00:22:21

Managing Toxicities of CDK4/6 Inhibitors in Hormone...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/16

In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.Key topics discussed include:•⁠ ⁠The evolving role of CDK4/6 inhibitors in early breast cancer

en

00:20:05

Treating and Managing Chronic Myeloid Leukemia (CML)...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/13

In this episode of the Oncology Brothers podcast, we welcomed back Dr. Jorge Cortes from the Georgia Cancer Center to discuss the latest updates in the management of Chronic Myeloid Leukemia (CML).Join us as we dive into the essential aspects of CML treatment, including:•⁠ ⁠The importance of initial workup and bone marrow biopsy in diagnosing CML.•⁠ ⁠Risk stratification and the selection of first-line therapies, including the latest TKIs like Asiminib and Ponatinib.•⁠ ⁠Patient-centered

en

00:23:23

How to Manage Thrombocytopenia (ITP, HIT, DIC, TTP) -...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/09

Welcome to the Oncology Brothers podcast! In this Challenging Cases episode, we take a deep dive into thrombocytopenia management—a common yet often perplexing topic in everyday hematology and oncology practice. We are joined by Dr. Ronak Mistry, hematologist at the University of Pennsylvania and co‑host of Fellows on Call, to walk through real‑world cases spanning ITP, anticoagulation with low platelets, and HIT.We covered essential topics such as:• Workup of thrombocytopenia and confirming the

en

00:25:30

IMforte - Maintenance Lurbinectedin + Atezo FDA...

Oncology Brothers: Practice-Changing Cancer Discussions ·

2025/10/06

In this episode of the Oncology Brothers podcast, we dive deep into the latest advancements in treating extensive stage small cell lung cancer (SCLC), focusing on the IMforte data and its clinical implications. We welcomed esteemed thoracic medical oncologists Drs. Isabel Preeshagul, Ticiana Leal, and Dr. Stephen Liu to discuss the findings presented at ASCO 2025 and World Lung 2025.Key topics included:• Overview of the IMforte study design and patient population• The role of lurbinectedin and

en

195 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

The Dry Eye Treatment PODCAST

Dry Eye Treatment

Différent et alors ?

PATRICK SULAY

Kyle Kingsbury Podcast

Kyle Kingsbury

The Real Weight Loss Coach

Matty Lansdown